Swissmedic to Enter GMP Information into EudraGMDP
The Swiss Agency for Therapeutic Products has begun entering GMP compliance information in the European Union’s EudraGMDP database.
On Feb. 21, 2019, the European Medicines Agency (EMA) announced that the Swiss Agency for Therapeutic Products (Swissmedic) has begun entering information on GMP compliance and marketing authorizations relating to Swiss manufacturers into the European Union’s EudraGMDP database as part of mutual recognition agreement (MRA) between the EU and Switzerland. New or renewed manufacturing authorizations and related GMP-certificates will be added using new templates that will replace the current paper documents. EMA stated in a press release that the new practice will “lead to easier information-sharing and efficiency gains for all stakeholders.”
The EudraGMDP database holds manufacturing, import, and wholesale-distribution authorizations as well as GMP and good distribution practice certificates, providing compliance status online for industry stakeholders. The MRA between the EU and Switzerland was updated in August 2017 to include an amendment on data entry by Swissmedic to EudraGMDP.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
